Mabion Past Earnings Performance
Past criteria checks 1/6
Mabion has been growing earnings at an average annual rate of 62.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 54.3% per year. Mabion's return on equity is 7.9%, and it has net margins of 9.2%.
Key information
62.3%
Earnings growth rate
63.1%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 54.3% |
Return on equity | 7.9% |
Net Margin | 9.2% |
Next Earnings Update | 25 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Mabion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 111 | 10 | 53 | 2 |
30 Jun 24 | 140 | 37 | 49 | 3 |
31 Mar 24 | 146 | 42 | 42 | 5 |
31 Dec 23 | 152 | 41 | 40 | 6 |
30 Sep 23 | 148 | 58 | 39 | 8 |
30 Jun 23 | 157 | 42 | 35 | 14 |
31 Mar 23 | 165 | 32 | 31 | 15 |
31 Dec 22 | 164 | 23 | 29 | 15 |
30 Sep 22 | 156 | 45 | 34 | 8 |
30 Jun 22 | 117 | 34 | 34 | 9 |
31 Mar 22 | 75 | 26 | 32 | 8 |
31 Dec 21 | 36 | 2 | 30 | 14 |
30 Sep 21 | 2 | -51 | 21 | 28 |
30 Jun 21 | 2 | -45 | 20 | 24 |
31 Mar 21 | 0 | -53 | 20 | 30 |
31 Dec 20 | 0 | -56 | 19 | 34 |
30 Sep 20 | 0 | -55 | 17 | 36 |
30 Jun 20 | 0 | -63 | 18 | 40 |
31 Mar 20 | 0 | -69 | 21 | 43 |
31 Dec 19 | 0 | -64 | 21 | 41 |
30 Sep 19 | 0 | -65 | 22 | 40 |
30 Jun 19 | 0 | -59 | 21 | 39 |
31 Mar 19 | 0 | -70 | 20 | 45 |
31 Dec 18 | 0 | -69 | 20 | 45 |
30 Sep 18 | 0 | -72 | 23 | 48 |
30 Jun 18 | 0 | -74 | 23 | 49 |
31 Mar 18 | 0 | -59 | 22 | 41 |
31 Dec 17 | 0 | -58 | 21 | 43 |
30 Sep 17 | 0 | -56 | 18 | 43 |
30 Jun 17 | 0 | -57 | 16 | 47 |
31 Mar 17 | 0 | -59 | 15 | 47 |
31 Dec 16 | 0 | -56 | 13 | 44 |
30 Sep 16 | 0 | -77 | 11 | 71 |
30 Jun 16 | 0 | -65 | 9 | 59 |
31 Mar 16 | 3 | -51 | 8 | 48 |
31 Dec 15 | 3 | -43 | 5 | 40 |
30 Sep 15 | 3 | -6 | 4 | 0 |
30 Jun 15 | 3 | -5 | 3 | 0 |
31 Mar 15 | 1 | -5 | 2 | 0 |
31 Dec 14 | 1 | -4 | 1 | 0 |
30 Sep 14 | 1 | -4 | 4 | 0 |
30 Jun 14 | 0 | -4 | 4 | 0 |
31 Mar 14 | 0 | -4 | 4 | 0 |
31 Dec 13 | 0 | -4 | 4 | 0 |
Quality Earnings: 272 has a large one-off loss of PLN13.3M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 272's current net profit margins (9.2%) are lower than last year (39.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 272 has become profitable over the past 5 years, growing earnings by 62.3% per year.
Accelerating Growth: 272's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 272 had negative earnings growth (-82.4%) over the past year, making it difficult to compare to the Biotechs industry average (-20.8%).
Return on Equity
High ROE: 272's Return on Equity (7.9%) is considered low.